Osataphan Nichanan, Chichareon Ply, Wongcharoen Wanwarang, Leemasawat Krit, Prasertwitayakij Narawudt, Suwannasom Pannipa, Gunaparn Siriluck, Rattanasumawong Kasem, Krittayaphong Rungroj, Phrommintikul Arintaya
Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Cardiology unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Clin Med (Lond). 2025 May;25(3):100322. doi: 10.1016/j.clinme.2025.100322. Epub 2025 Apr 30.
The Atherosclerotic Risk in Communities (ARIC) heart failure (HF) score was originally developed in the USA to predict new-onset HF. Our goal was to validate the ARIC-HF score and develop a new score to predict HF in an Asian population.
The Cohort Of patients with high Risk for cardiovascular Events (CORE-Thailand) was a prospective registry of Thai patients with high atherosclerotic risk. Patients were followed for 5 years for HF events. The ARIC-HF score was applied to predict HF. The new ARIC-CORE score was developed by re-estimating the coefficients of ARIC score variables using ridge regression. The discrimination and calibration of the models were assessed. The net reclassification index (NRI) was used to compare the prediction performance between the models. Clinical utility was assessed with a decision curve analysis.
From a total of 8,919 patients, 185 (2.1 %) developed HF. The ARIC-HF score and ARIC-CORE HF risk score provided good discrimination with C-statistics of 0.710, (95 % confidence interval (CI); 0.673-0.747) and 0.75, (95 % CI; 0.715-0.785), respectively. Both models showed a good calibration. Using the ARIC-CORE HF score was associated with an improved reclassification of HF (NRI 0.369, 95 % CI; 0.286-0.551) compared to the ARIC-HF score. The net clinical benefit of the ARIC-CORE HF score was higher than the ARIC-HF score in the decision curve analysis.
The ARIC-HF score performed well in predicting heart failure in the CORE population. The ARIC-CORE HF score showed superior predictive ability and clinical benefit. Further research is needed to validate these models in diverse Asian populations.
社区动脉粥样硬化风险(ARIC)心力衰竭(HF)评分最初是在美国开发的,用于预测新发HF。我们的目标是验证ARIC-HF评分,并开发一种新的评分来预测亚洲人群中的HF。
心血管事件高风险患者队列(泰国CORE)是一项针对泰国动脉粥样硬化高风险患者的前瞻性登记研究。对患者进行了5年的HF事件随访。应用ARIC-HF评分预测HF。通过使用岭回归重新估计ARIC评分变量的系数,开发了新的ARIC-CORE评分。评估了模型的区分度和校准度。使用净重新分类指数(NRI)比较模型之间的预测性能。通过决策曲线分析评估临床实用性。
在总共8919名患者中,185名(2.1%)发生了HF。ARIC-HF评分和ARIC-CORE HF风险评分具有良好的区分度,C统计量分别为0.710(95%置信区间(CI):0.673-0.747)和0.75(95%CI:0.715-0.785)。两个模型均显示出良好的校准度。与ARIC-HF评分相比,使用ARIC-CORE HF评分与HF的重新分类改善相关(NRI 0.369,95%CI:0.286-0.551)。在决策曲线分析中,ARIC-CORE HF评分的净临床益处高于ARIC-HF评分。
ARIC-HF评分在预测CORE人群中的心力衰竭方面表现良好。ARIC-CORE HF评分显示出卓越的预测能力和临床益处。需要进一步研究以在不同的亚洲人群中验证这些模型。